M.D., D Chair in Urologic Oncology; Chief, Genitourinary Oncology Service; Member and Attending Physician, Department of Medicine, Memorial Sloan Kettering Cancer Center; Professor of Medicine Weill Cornell Medical College
Howard I. Scher, MD has helped elucidate key molecular and genetic features of prostate cancer and has translated these insights into the clinical evaluation of novel targeted agents including abiraterone and enzalutamide. His research is focused on the validation of circulating tumor cell and other blood based biomarker assays to biologically profile individual patient tumors to better select and monitor the effects of therapy. Dr. Scher led the international Prostate Cancer Clinical Trials Working Group effort standardize the design and analysis of phase II trials, and serves as the principal investigator of an NIH-supported Specialized Program of Research Excellence in Prostate Cancer, Prostate Cancer Clinical Trials Consortium and the Department of Defense Transformative Impact Award: Toward the Practice of Precision Medicine – A Biomarker Validation Coordinating Center.
Session Abstract – PMWC 2017 Silicon Valley
Session Synopsis: The Cancer Moonshot’s Blood Profiling Atlas aims to accelerate the development and approval of accurate blood tests for cancer diagnosis and precision treatment. This PMWC panel of Cancer Moonshot participants discusses progress in creating an open database of liquid biopsy results and developing safe and effective blood profiling diagnostics.